Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase 1 3Phase 4 1

Status

Unknown 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 3Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Immune Checkpoint Inhibitors × Clear all
NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06076135 2025-06-15

ILDR-01

Shantou University Medical College

Phase 2 Active not recruiting
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06472713 2025-01-13

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Sun Yat-sen University

Phase 2 Recruiting
32 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05520814 2023-09-21

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05530200 2022-09-07

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
56 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡